Research programme: GlycoPEGylated erythropoietin - BioGeneriX/Neose

Drug Profile

Research programme: GlycoPEGylated erythropoietin - BioGeneriX/Neose

Alternative Names: GlycoPEG-CHO-EPO

Latest Information Update: 09 Jan 2007

Price : $50

At a glance

  • Originator BioGeneriX; Neose Technologies
  • Class
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Neutropenia

Most Recent Events

  • 30 Dec 2006 Discontinued - Preclinical for Neutropenia in USA (unspecified route)
  • 28 Apr 2005 Neose Technologies and BioGeneriX have entered into a research, licence and option agreement for an undisclosed protein
  • 15 Feb 2005 Early research in Undefined in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top